The US Food and Drug Administration (FDA) has approved Cyramza (ramucirumab) for the treatment of Gastric Cancer on April 2014. This drug is specially recommended for the treatment of patients suffering from advanced gastric cancer who has been treated previously with fluoropyrimidine- or platinum-containing chemotherapy.
Cyramza is a recombinant human IgG1 monoclonal antibody which specifically binds to vascular endothelial growth factor receptor 2. It functions as an angiogenesis inhibitor and inhibits blood supply to tumor cell and thus inhibit tumor growth and progression.
This Drug is available as a solution for intravenous infusion and has to be administered every two weeks over 60 minutes. The recommended dose is 8 mg/kg. The common side effects of this drug are hypertension and diarrhea.
US FDA approved Cyramza on basis of a multinational, randomized, double-blind study evaluating Cyramza plus best supportive care (BSC) versus placebo plus BSC. The study was conducted in 355 subjects suffering from locally advanced or metastatic gastric cancer (including adenocarcinoma of the gastro-esophageal junction) who previously received platinum- or fluoropyrimidine-containing chemotherapy. The subjects treated with Cyramza experienced an increased median overall survival compared to those treated with placebo. Tumor growth was also delayed in patients after treatment with Cyramza. Thus this drug has provided a new horizon for the treatment of advanced gastric cancer.
More information on Cyramza can be obtained from-http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1320/cyramza-ramucirumab
Clinnovo is a clinical innovation company. It is pioneer CRO industry in India. Clinnovo offers professional Clinical Research Course, clinical data management course , SAS and imaging training. Clinnovo has been serving different bio-pharma industries across the world with excellence and high quality. For more information contact at +91 9912868928, 040 64635501
No comments:
Post a Comment